Literature DB >> 22917935

Posterior reversible encephalopathy syndrome (PRES) after treatment with oxaliplatin and 5-fluorouracil.

Nicholas Truman1, Daniel Nethercott.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22917935     DOI: 10.1016/j.clcc.2012.06.003

Source DB:  PubMed          Journal:  Clin Colorectal Cancer        ISSN: 1533-0028            Impact factor:   4.481


× No keyword cloud information.
  7 in total

1.  Correlation analysis of STAT3 and VEGF expression and eosinophil infiltration in nasal polyps.

Authors:  Qingsong Cao; Tao Zhang; Jie Zhang
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-09-25       Impact factor: 2.503

2.  Posterior reversible encephalopathy syndrome resulting from repeat bortezomib usage.

Authors:  N A Nixon; K Parhar
Journal:  BMJ Case Rep       Date:  2014-06-05

Review 3.  Chemotherapy-associated Posterior Reversible Encephalopathy Syndrome: A Case Report and Review of the Literature.

Authors:  Joan How; Margaret Blattner; Susan Fowler; Andrea Wang-Gillam; Suzanne E Schindler
Journal:  Neurologist       Date:  2016-11       Impact factor: 1.398

4.  Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy.

Authors:  Hee Jung Yi; Kyung Sook Hong; Nara Moon; Soon Sup Chung; Ryung-Ah Lee; Kwang Ho Kim
Journal:  Ann Surg Treat Res       Date:  2016-02-26       Impact factor: 1.859

5.  Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES).

Authors:  Taimoor Khalid Janjua; Muhammad Hassan; Hira Khan Afridi; Naila Anjum Zahid
Journal:  BMJ Case Rep       Date:  2017-10-04

6.  The first two cases of posterior reversible encephalopathy syndrome (PRES) secondary to conventional transcatheter arterial chemoembolization of hepatocellular carcinoma.

Authors:  Kefeng Jia; Weili Yin; Fang Wang; Zhongsong Gao; Cheng Sun; Hui Wang; Yujuan Han; Yongmei Wang; Mingge Li; Changlu Yu
Journal:  BMC Gastroenterol       Date:  2021-12-20       Impact factor: 3.067

7.  Posterior Reversible Encephalopathy Syndrome Associated with Oxaliplatin Use for Pancreatic Adenocarcinoma.

Authors:  David G Symeonidis; Alexandros D Liatsos; Evridiki K Mazlimoglou; Eleni C Geraki; Christos Kosmas
Journal:  Case Rep Oncol       Date:  2021-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.